Follow
Leonidas Nikolaos Diamantopoulos
Leonidas Nikolaos Diamantopoulos
Verified email at cc.uoi.gr
Title
Cited by
Cited by
Year
Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm?
A Fountas, LN Diamantopoulos, A Tsatsoulis
Trends in Endocrinology & Metabolism 26 (11), 643-656, 2015
952015
Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
AR Khaki, A Li, LN Diamantopoulos, MA Bilen, V Santos, J Esther, ...
Cancer 126 (6), 1208-1216, 2020
752020
Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors
D Michailidou, AR Khaki, MP Morelli, L Diamantopoulos, N Singh, ...
Scientific reports 11 (1), 9029, 2021
482021
A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors
AR Khaki, A Li, LN Diamantopoulos, NJ Miller, L Carril-Ajuria, ...
European urology oncology 4 (3), 464-472, 2021
442021
Histological subtypes and response to PD-1/PD-L1 blockade in advanced urothelial cancer: a retrospective study
NJ Miller, AR Khaki, LN Diamantopoulos, MA Bilen, V Santos, N Agarwal, ...
The Journal of urology 204 (1), 63-70, 2020
362020
Prognostic factors for survival among patients with small bowel neuroendocrine tumours associated with mesenteric desmoplasia
FM Laskaratos, L Diamantopoulos, M Walker, H Walton, M Khalifa, ...
Neuroendocrinology 106 (4), 366-380, 2018
282018
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes
LN Diamantopoulos, AR Khaki, P Grivas, JL Gore, GR Schade, AC Hsieh, ...
Bladder Cancer 6 (1), 71-81, 2020
222020
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
SM Esagian, AR Khaki, LN Diamantopoulos, L Carril‐Ajuria, D Castellano, ...
BJU international 128 (2), 196-205, 2021
212021
Antiproliferative effect of above-label doses of somatostatin analogs for the management of gastroenteropancreatic neuroendocrine tumors
LN Diamantopoulos, FM Laskaratos, M Kalligeros, R Shah, ...
Neuroendocrinology 111 (7), 650-659, 2021
162021
Safety of immunizations for the adult patient with inflammatory bowel disease—a systematic review and meta-analysis
A Desalermos, M Pimienta, M Kalligeros, F Shehadeh, L Diamantopoulos, ...
Inflammatory Bowel Diseases 28 (9), 1430-1442, 2022
152022
Response to neoadjuvant chemotherapy and survival in micropapillary urothelial carcinoma: data from a tertiary referral center and the surveillance, epidemiology, and end …
LN Diamantopoulos, SK Holt, AR Khaki, RR Sekar, A Gadzinski, ...
Clinical genitourinary cancer 19 (2), 144-154, 2021
142021
Central nervous system metastasis in patients with urothelial carcinoma: institutional experience and a comprehensive review of the literature
LN Diamantopoulos, AR Khaki, GP Sonpavde, VA Venur, YY Evan, ...
Clinical genitourinary cancer 18 (3), e266-e276, 2020
122020
Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration
P Ravi, GR Pond, LN Diamantopoulos, C Su, A Alva, RK Jain, ...
BJU international 128 (5), 607-614, 2021
112021
Biomarkers in small intestine NETs and carcinoid heart disease: a comprehensive review
M Kalligeros, L Diamantopoulos, C Toumpanakis
Biology 10 (10), 950, 2021
112021
Association between sites of metastasis and outcomes with immune checkpoint inhibitors in advanced urothelial carcinoma
D Makrakis, R Talukder, GI Lin, LN Diamantopoulos, S Dawsey, S Gupta, ...
Clinical genitourinary cancer 20 (5), e440-e452, 2022
102022
Sarcomatoid urothelial carcinoma: a population-based study of clinicopathologic characteristics and survival outcomes
LN Diamantopoulos, D Korentzelos, M Alevizakos, JL Wright, P Grivas, ...
Clinical Genitourinary Cancer 20 (2), 139-147, 2022
82022
Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy
LN Diamantopoulos, RR Sekar, SK Holt, AR Khaki, NJ Miller, A Gadzinski, ...
Urologic Oncology: Seminars and Original Investigations 39 (8), 496. e1-496. e8, 2021
82021
Treatment rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma
D Makrakis, DR Bakaloudi, R Talukder, GI Lin, LN Diamantopoulos, ...
Clinical genitourinary cancer 21 (2), 286-294, 2023
72023
Bladder cancer multidisciplinary clinic (BCMC) model influences disease assessment and impacts treatment recommendations
LN Diamantopoulos, BR Winters, P Grivas, SD Ngo, J Zeng, AC Hsieh, ...
Bladder Cancer 5 (4), 289-298, 2019
72019
Association of the time to immune checkpoint inhibitor (ICI) initiation and outcomes with second line ICI in patients with advanced urothelial carcinoma
R Talukder, D Makrakis, GI Lin, LN Diamantopoulos, S Dawsey, S Gupta, ...
Clinical genitourinary cancer 20 (6), 558-567, 2022
62022
The system can't perform the operation now. Try again later.
Articles 1–20